Enzolytics Inc (ENZC)

[Tkmoney1]

1) Samsung Biologics......I realize that Samsung Biologics claims to go from gene to IND in 9 months, but from the companies I've seen so far that has not been the case. Now, these companies started with Samsung in 2018 or so, so maybe the technology and speed today can get in done much faster, but from what I see it's around 2 yrs before approval.......https://www.prnewswire.com/news-releases/samsung-biologics-national-oncoventure-and-eutilex-obtain-ind-approval-from-fda-301215739.html........https://www.pressreader.com/korea-republic/the-korea-times/20200424/281509343331449

2) Audited Financials...... Obviously this has not gone the way ENZC or any of us wanted from the beginning and the hiring of M&B. Remember M&B said we did a reverse merger not a business combination, so we needed the books of Bioclonetics to also be audited for those 2 yrs, which it turned out we actually did do a business combination. So that was obviously a huge issue 6 months into the auditing process. They even hired Steven Heumann from Eisner & Amper to assist with this. Unless Charles is lying in the quarterly reports, he always maintained there was no issues or questions from M&B, and he provided them with all the necessary documentation. Now what was the straw that broke the camels back this summer that caused them to fire M&B, is anyones guess. But you simply don't go through this length to get an audit done, hire independent counsel, to not ultimately get the audit completed. When will this happen? Who knows but I would expect either this month or next at the latest.

3) IPF IMMUNE......Now this is the one the optically looks the worse, as we initially came out with a PR back in Nov 21 talking about introducing IPF in early 2022. It was definitely hyped/pumped leading up to the supposed release in March. Everything seemed to be a go as Onelavi took orders, product was supposedly here as we saw evidence of, and then the FDA label issue. Coincidence? Maybe, but we know how things sometimes go with the powers that be. Turns out supply was also an issue so it has given them time to hopefully get stocked up and prepared for the release soon.


Final note......ENZC is a drug development co, and the business combination that took place between Charles & Harry back in 2020, also coincided with greatest pump in OTC history, which caused ENZC to go from trip zeros to almost a dollar in less than 6 months. Where we were at in that particular time, there was literally no place for ENZC to go but way down. They could have been absolutely perfect with everything they did and this would have still took a massive hit, these are just the facts imo. To say it's a longshot to get a drug to market is a understatement to say the least, and many people will bash and hate on ENZC no doubt, and a overwhelming majority of the time they will be correct, just like almost all OTC stocks/companies will never go anywhere. But nobody can say for certain either way, as we are not even in pre-clinical trials yet for there 2 major drugs, ITV-1 & Clone 3. As we sit at just above .04 cents, I can't think of many other OTC companies that have the kind of verticals we have in the biotech space, that have only diluted once in the amount of 32 million shares, and I believe those were restricted. Delays and mistakes, sure. But the fact that they have not reached into investors pockets the last 2 yrs should speak volumes imo, as the overhead costs are extremely low and exactly what you would want from a co like ENZC with basically 4-6 employees. It will all eventually boil down to the science, and then we can all judge whether or not ENZC was a success or failure. But it's also the reason you can still buy it for pennies, with a lot risk right now but also could be very rewarding.